155180-53-3 Usage
Description
RU 59063, also known as 4-[4,4-Dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile, is a chemical compound with potential applications in the field of cancer research and treatment. It is characterized by its unique molecular structure, which allows it to interact with specific biological targets and modulate cellular processes.
Uses
Used in Anticancer Applications:
RU 59063 is used as a precursor for the preparation of Proteolysis Targeting Chimeras (PROTACs), which are a novel class of therapeutic agents with potential anticancer effects. These PROTACs work by promoting the degradation of specific proteins involved in cancer cell survival and proliferation, thereby inhibiting tumor growth and progression.
Used in Drug Development:
In the pharmaceutical industry, RU 59063 is used as a key intermediate in the synthesis of various drug candidates targeting cancer. Its unique chemical properties make it a valuable building block for the development of new and innovative therapeutic agents.
Used in Research and Development:
RU 59063 is also utilized in academic and industrial research settings to study the underlying mechanisms of cancer and to identify potential targets for therapeutic intervention. Its use in these applications contributes to the advancement of our understanding of cancer biology and the development of more effective treatment strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 155180-53-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,5,1,8 and 0 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 155180-53:
(8*1)+(7*5)+(6*5)+(5*1)+(4*8)+(3*0)+(2*5)+(1*3)=123
123 % 10 = 3
So 155180-53-3 is a valid CAS Registry Number.
InChI:InChI=1/C17H18F3N3O2S/c1-16(2)14(25)23(15(26)22(16)7-3-4-8-24)12-6-5-11(10-21)13(9-12)17(18,19)20/h5-6,9,24H,3-4,7-8H2,1-2H3
155180-53-3Relevant articles and documents
Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat
Barrett, Ryan R.G.,Nash, Claire,Diennet, Marine,Cotnoir-White, David,Doyle, Christopher,Mader, Sylvie,Thomson, Axel A.,Gleason, James L.
supporting information, (2021/12/01)
The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a se
Phenylimidazolidines having antiandrogenic activity
-
, (2008/06/13)
A compound of the formula STR1 wherein R1 is --CN, --NO2 or halogen, R2 is --CF3 or halogen, --A--B-- is of STR2 X is --O-- or --S--, R3 is hydrogen, alkyl, alkenyl or alkynyl of up to 12 carbon atoms, aryl and aralkyl of up to 12 carbon atoms, all optionally substituted by --OH, halogen, --SH, --CN, acyl and acyloxy of up to 7 carbon atoms, --aryl, --O--aryl, --O--aralkyl --S-- aryl of up to 12 carbon atoms the aryl and aralkyl being optionally substituted by halogen, --CF3, alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl or alkynyloxy with the sulfur being optionally oxidized to sulfone or sulfoxide, free, esterified, amidified or salified carboxy, --NH2, mono and dialkylamino and heterocyclic of 3 to 6 ring members and containing at least one heteroatom selected from the group consisting of oxygen, sulfur and nitrogen, the alkyl, alkenyl and alkynyl being optionally interrupted by at least one oxygen, nitrogen or sulfur optionally oxidized to sulfoxide or sulfone, trialkylsilyl with the alkyl having 1 to 6 carbon atoms and acyl and acyloxy of an organic carboxylic acid of 1 to 7 carbon atoms and Y is --O--, --S-- or --NH--, except the compounds wherein --A-B-- is STR3 X is oxygen, R3 is hydrogen and Y is oxygen or --NH--, R2 is --CF3 or halogen and R1 is --NO2 or halogen and their non-toxic, pharmaceutically acceptable acid addition salts.
